Compare PACK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | CHRS |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 296.8M |
| IPO Year | 2017 | 2014 |
| Metric | PACK | CHRS |
|---|---|---|
| Price | $5.62 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.50 | $5.51 |
| AVG Volume (30 Days) | 460.8K | ★ 945.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $9.29 | $73.08 |
| Revenue Next Year | $8.35 | $30.94 |
| P/E Ratio | ★ N/A | $1.24 |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $2.91 | $0.72 |
| 52 Week High | $6.31 | $2.62 |
| Indicator | PACK | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 76.10 | 51.75 |
| Support Level | $5.20 | $1.55 |
| Resistance Level | $5.83 | $1.89 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 94.84 | 33.33 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.